Cohort of patients with systemic sclerosis at Brest University Hospital

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study involves a prospective cohort of adult patients diagnosed with systemic sclerosis. It aims to collect longitudinal clinical data and biological samples, including blood, stool, and skin swabs for microbiota analysis. Participants will also complete questionnaires assessing their quality of life, pain, and disability. The study is conducted at the reference center for rare autoimmune diseases at Brest University Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Major patient with systemic sclerosis defined according to the EULAR 2013 criteria (see Appendix 1)
* Patient evaluated within the framework of the reference center for rare autoimmune diseases of the CHU of Brest.
* Patient affiliated to the social security system
* Patient having signed a written informed consent.

Exclusion Criteria:

* Minor
* Patient under legal protection (guardianship, curatorship)
* Refusal to participate
* Patient unable to consent
* Pregnant or breastfeeding woman
* Hemoglobin (Hb) level \< 7g/dl

Where it's running

• CHRU de Brest
  Brest, France Recruiting

Study contacts

• Study coordinator: Claire DE MOREUIL
• Email: claire.demoreuil@chu-brest.fr
• Phone: 0033298145303

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Test of HBM7020 in healthy adults and adults with autoimmune diseases

  This first-in-human study tests whether HBM7020 is safe and how it acts in the body for people with autoimmune diseases like RA, SLE, Sjögren's, and SSc compared with healthy volunteers.

  Recruiting Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Brisbane, Queensland · NCT07649265

• Anti-CD19/BCMA universal CAR-T cell therapy for refractory autoimmune diseases

  This will try anti-CD19/BCMA universal CAR-T cell therapy in adults with refractory rheumatoid arthritis, dermatomyositis, systemic lupus, or systemic sclerosis to see if it is safe and can control their disease.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07558850

• Immun4Cure Cohort of Autoimmune Diseases

  A long-term, 500-person database and biobank is being built to study autoimmune diseases like RA, SLE, and scleroderma, plus healthy adults, using deep profiling and regular follow-ups over five years.

  Recruiting University Hospital, Montpellier · Montpellier · NCT07515638

• Nerandomilast for Systemic Sclerosis in Adults

  This study tests whether nerandomilast tablets can help adults with systemic sclerosis compared to a placebo.

  Recruiting at 67 sites Phase 3 Boehringer Ingelheim · Birmingham, Alabama and 247 other locations · NCT07497087

• AZD0120 CD19/BCMA CAR T-cell therapy for systemic sclerosis, inflammatory myopathies, and difficult-to-treat rheumatoid arthritis

  This trial will try a dual-targeting CD19/BCMA CAR T-cell treatment (AZD0120) in adults with systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis to see if it is safe and well tolerated.

  Recruiting at 5 sites Phase 1/2 AstraZeneca · Tucson, Arizona and 26 other locations · NCT07295847

• Phase 1 safety test of XmAb657 in healthy adults and people with myositis, scleroderma, or Sjögren's

  This study will test whether subcutaneous injections of XmAb657 are safe and well tolerated in healthy adults and people with autoimmune diseases such as idiopathic inflammatory myopathies, systemic sclerosis, or primary Sjögren's syndrome.

  Recruiting Phase 1 Xencor, Inc. · Melbourne · NCT07284797

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.